Inventor · disambiguated record
Antje Margret Wengner
Also filed as: WENGNER ANTJE · WENGNER ANTJE MARGRET
29 granted patents·24 pending applications·70 citations·filing 2010–2024
94Inventor score
Top patents by PatentIndex Score
53 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0293US10729680B25-substituted 2-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2017·Granted Aug 4, 2020·10 cites·14 claims
- 0389US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0488US11142522B2Compounds, compositions and methods for cancer treatmentBROAD INST INC·Filed 2018·Granted Oct 12, 2021·4 cites·16 claims
- 0585US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0685US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 0783US2024366620A1Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2024·Application pending·0 cites
- 0881US11976334B2Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative diseaseBAYER AG·Filed 2021·Granted May 7, 2024·1 cites·6 claims
- 0980US11712440B2Predictive markers for ATR kinase inhibitorsBAYER AG·Filed 2018·Granted Aug 1, 2023·1 cites·3 claims
- 1080US9999623B2Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomasBayer Pharma AG·Filed 2014·Granted Jun 19, 2018·6 cites·3 claims
- 1180US9670202B2Substituted triazolopyridinesBayer Pharma AG·Filed 2014·Granted Jun 6, 2017·2 cites·16 claims
- 1279US10966986B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2017·Granted Apr 6, 2021·1 cites·8 claims
- 1379US10226469B2Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomasBayer Pharma AG·Filed 2018·Granted Mar 12, 2019·3 cites·8 claims
- 1478US10266548B2Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2017·Granted Apr 23, 2019·2 cites·2 claims
- 1575US9255100B2Substituted imidazopyridazinesKLAR ULRICH·Filed 2011·Granted Feb 9, 2016·3 cites·14 claims
- 1674US12053476B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2021·Granted Aug 6, 2024·0 cites·6 claims
- 1773US2023346927A1COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORSBAYER AG·Filed 2023·Application pending·0 cites
- 1872US9540392B2ThienopyrimidinesBayer Pharma AG·Filed 2013·Granted Jan 10, 2017·2 cites·10 claims
- 1969US2022241261A1Combinations of inhibitors of irak4 with inhibitors of btkBayer Pharma AG·Filed 2021·Application pending·0 cites
- 2067US2019388410A1Combinations of inhibitors of irak4 with inhibitors of btkBayer Pharma AG·Filed 2019·Application pending·0 cites
- 2166US11690911B2Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitorsBayer Pharma AG·Filed 2018·Granted Jul 4, 2023·0 cites·15 claims
- 2265US9663510B2Substituted triazolopyridines and their use as TTK inhibitorsBAYER IP GMBH·Filed 2012·Granted May 30, 2017·1 cites·27 claims
- 2364US10604532B2Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2019·Granted Mar 31, 2020·0 cites·6 claims
- 2463US8551980B2Substituted triazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Oct 8, 2013·1 cites·13 claims
- 2561US2025066370A1Bicyclic triazine derivatives for the treatment of cancerDEUTSCHES KREBSFORSCH·Filed 2023·Application pending·0 cites
- 2657US2018289685A1Combinations of inhibitors of irak4 with inhibitors of btkBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2756US2024108766A1Lrrc15 antibodies and conjugates thereofBAYER AG·Filed 2022·Application pending·0 cites
- 2854US2016175306A1Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancerBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2954US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 3054US2023192700A1Pyrazolopyrazines acting on cancers via inhibition of cdk12BAYER AG·Filed 2021·Application pending·0 cites
- 3153US2023106032A1Imidazotriazines acting on cancer via inhibition of cdk12BAYER AG·Filed 2021·Application pending·0 cites
- 3252US2014249133A1Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseasesBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 3352US2021369724A1Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compoundsBAYER AG·Filed 2019·Application pending·0 cites
- 3451US9512130B2Substituted imidazopyridazinesBayer Pharma AG·Filed 2014·Granted Dec 6, 2016·0 cites·10 claims
- 3551US2023117034A1PyrazolotriazinesBAYER AG·Filed 2020·Application pending·0 cites
- 3649US11660301B2Combination of ATR kinase inhibitors with PARP inhibitorsBayer Pharma AG·Filed 2018·Granted May 30, 2023·0 cites·29 claims
- 3747US9682995B2Amino-substituted isothiazolesBayer Pharma AG·Filed 2014·Granted Jun 20, 2017·0 cites·15 claims
- 3845US2022117973A1The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative diseaseBAYER AG·Filed 2020·Application pending·0 cites
- 3945US2016128988A1Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitorBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4044US9586958B2Prodrug derivatives of substituted triazolopyridinesBayer Pharma AG·Filed 2014·Granted Mar 7, 2017·0 cites·14 claims
- 4144US9512126B2Substituted imidazopyridazinesBAYER IP GMBH·Filed 2013·Granted Dec 6, 2016·0 cites·16 claims
- 4244US2016207928A1Novel compounds for the treatment of cancerBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4343US2020063212A1An inhibitor of atr kinase for use in a method of treating a hyper-proliferative diseaseBAYER AG·Filed 2018·Application pending·0 cites
- 4442US2016264568A1Substituted triazolopyridines having activity as mps-1 inhibitorsBayer Pharma AG·Filed 2014·Application pending·0 cites
- 4540US10894784B2Heteroarylbenzimidazole compoundsBayer Pharma AG·Filed 2016·Granted Jan 19, 2021·0 cites·15 claims
- 4638US2014255392A1Substituted imidazopyridines and intermediates thereofKOPPITZ MARCUS·Filed 2012·Application pending·0 cites
- 4737US2014120087A1TriazolopyridinesSCHULZE VOLKER·Filed 2012·Application pending·0 cites
- 4836US2017342064A1Compounds for the treatment of cancerBayer Pharma AG·Filed 2015·Application pending·0 cites
- 4935US10214545B2Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disordersBayer Pharma AG·Filed 2015·Granted Feb 26, 2019·0 cites·21 claims
- 5034US9676766B2TriazolopyridinesSCHULZE VOLKER·Filed 2010·Granted Jun 13, 2017·0 cites·14 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Antje Margret Wengner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →